Annovis Bio, Inc. SEC filings ANVS
Annovis Bio, Inc. has 314 filings in SEC EDGAR's recent list, going back to Jan 15, 2010. Its latest annual report, Form 10-K, was filed on Mar 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (material agreement, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Nov 4, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Oct 30, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Oct 20, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Other events
|
Jul 10, 2026 | Jul 7, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
May 20, 2026 | May 20, 2026 |
| 8-K |
Current report
Results of operations
|
May 15, 2026 | May 15, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Apr 10, 2026 | Apr 9, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 25, 2026 | Mar 23, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 16, 2026 | Mar 16, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 12, 2026 | Feb 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 28, 2026 | Jan 28, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 28, 2025 | Oct 26, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Oct 14, 2025 | Oct 10, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 29, 2025 | Sep 25, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 15, 2025 | Aug 11, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 20, 2025 | Jun 19, 2025 |
| 8-K |
Current report
Results of operations, Officer or director change
|
May 13, 2025 | May 9, 2025 |
| 8-K |
Current report
Listing notice, Officer or director change, Regulation FD disclosure
|
Mar 27, 2025 | Mar 26, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 21, 2025 | Mar 21, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 5, 2025 | Feb 5, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Feb 5, 2025 | Feb 3, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 11, 2024 | Dec 11, 2024 |
| 8-K |
Current report
Material agreement
|
Dec 11, 2024 | Dec 11, 2024 |
| 8-K |
Current report
Officer or director change
|
Dec 9, 2024 | Dec 4, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2024 | Nov 12, 2024 |
| 8-K |
Current report
Other events
|
Oct 15, 2024 | Oct 15, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 30, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 15, 2024 | Aug 15, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 6, 2024 | Aug 6, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 16, 2024 | Jul 16, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 10, 2024 | Jul 10, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 2, 2024 | Jul 2, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2024 | Jun 13, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 11, 2024 | Jun 11, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 5, 2024 | Jun 5, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
May 21, 2024 | May 21, 2024 |
| 8-K |
Current report
Results of operations
|
May 13, 2024 | May 13, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
May 9, 2024 | May 9, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
May 6, 2024 | May 6, 2024 |
| 8-K |
Current report
Other events
|
May 2, 2024 | May 2, 2024 |
| 8-K |
Current report
Officer or director change
|
May 1, 2024 | May 1, 2024 |
| 8-K |
Current report
Material agreement
|
Apr 26, 2024 | Apr 25, 2024 |
| 8-K |
Current report
Results of operations
|
Apr 3, 2024 | Apr 2, 2024 |
| 8-K |
Current report
Other events
|
Mar 22, 2024 | Mar 22, 2024 |
| 8-K |
Current report
Material agreement
|
Mar 21, 2024 | Mar 21, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 20, 2024 | Mar 20, 2024 |
| 8-K |
Current report
Other events
|
Mar 20, 2024 | Mar 19, 2024 |
| 8-K |
Current report
Material agreement
|
Mar 15, 2024 | Mar 15, 2024 |
| 8-K |
Current report
Material agreement, Results of operations, Other events
|
Nov 1, 2023 | Oct 30, 2023 |
| 8-K |
Current report
Other events
|
Oct 30, 2023 | Oct 30, 2023 |
| 8-K |
Current report
Other events
|
Oct 13, 2023 | Oct 10, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 16, 2023 | Jun 16, 2023 |
| 8-K |
Current report
Auditor change
|
May 30, 2023 | May 30, 2023 |
| 8-K |
Current report
Agreement ended, Other events
|
Apr 4, 2023 | Apr 4, 2023 |
| 8-K |
Current report
Material agreement
|
Apr 3, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
Apr 3, 2023 | Apr 3, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 31, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Restatement
|
Mar 6, 2023 | Feb 28, 2023 |
| 8-K |
Current report
Other events
|
Feb 13, 2023 | Feb 13, 2023 |
| 8-K |
Current report
Other events
|
Jan 6, 2023 | Jan 6, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 12, 2022 | Sep 9, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 30, 2022 | Aug 29, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2022 | Aug 8, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2022 | Jun 2, 2022 |
| 8-K |
Current report
Results of operations
|
May 4, 2022 | May 4, 2022 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Nov 15, 2021 | Nov 15, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 12, 2021 | Nov 12, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 5, 2021 | Oct 5, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 11, 2021 | Aug 11, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 29, 2021 | Jul 28, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2021 | Jun 1, 2021 |
| 8-K |
Current report
Material agreement, Other events
|
May 24, 2021 | May 21, 2021 |
| 8-K |
Current report
Officer or director change
|
Apr 15, 2021 | Apr 9, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 23, 2021 | Mar 23, 2021 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Mar 15, 2021 | Mar 14, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 9, 2020 | Jun 9, 2020 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2020 | Jun 3, 2020 |
| 8-K |
Current report
Other events
|
Apr 3, 2020 | Apr 3, 2020 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Feb 6, 2020 | Jan 30, 2020 |
Showing 86 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANVS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Malvern, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1477845
- Former names
- QR Pharma, Inc. (until Mar 15, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.